Table 3 Cardiac biomarkers assayed at index hospitalization for patients with and without COVID-19 infection.
Biomarker laboratories | COVID-19 Hospitalization (N = 257,075) | No COVID-19 Hospitalization (N = 330,255) | ||
|---|---|---|---|---|
Number tested | Median (25%–75%) | Number tested | Median (25%–75%) | |
Natriuretic peptides | ||||
BNP (pg/mL) | 29,551 (11%) | 50 (21–133) | 10,580 (3%) | 74 (30–203) |
NT-proBNP (pg/mL) | 34,251 (13%) | 185 (59–696) | 9442 (3%) | 286 (83–996) |
Cardiac troponins | ||||
Troponin I (ng/mL) | 30,496 (12%) | 0.02 (0.01–0.05) | 16,058 (5%) | 0.02 (0.01–0.07) |
Troponin T (ng/mL) | 22,105 (9%) | 0.01 (0.01–0.03) | 10,517 (3%) | 0.01 (0.01–0.03) |
Subsequent Heart Failure (N = 5879) | No Subsequent Heart Failure (N = 251,196) | Subsequent Heart Failure (N = 5100) | No Subsequent Heart Failure (N = 325,155) | |
Elevated | 1103 | 23,302 | 598 | 8588 |
Natriuretic Peptide* | (19%) | (9%) | (12%) | (3%) |
